Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1651–1658. doi: 10.1158/1055-9965.EPI-08-1041

Table 2. Tag-SNPs associated with risk of glioma at p-trend<0.01 in pooled hospital-based case-control study of adult glioma conducted by the National Cancer Institute (NCI) and population-based case-control study of adult glioma conducted by the National Institute for Occupational Safety and Health (NIOSH).

NCI NIOSH Pooled

Region
Gene
SNP ID Genotype Control
N (%)
Case
N (%)
OR1,2 95% CI3 Control
N (%)
Case
N (%)
OR4 95% CI OR5 95% CI
SELP
 SELP rs39177276 AA 132 (40.1) 129 (49.2) 1.00 213(39.8) 137(48.1) 1.00 1.00
AG 155 (47.1) 102 (38.9) 0.67 0.47-0.96 246(46.0) 122(42.8) 0.72 0.52-1.00 0.70 0.55-0.89
GG 42 (12.8) 31 (11.8) 0.79 0.46-1.35 76 (14.2) 26 (9.1) 0.51 0.30-0.87 0.63 0.43-0.91
P trend 0.103 0.005 0.001
rs22368686 GG 86 (26.2) 91 (34.6) 1.00 140(26.3) 94 (32.8) 1.00 1.00
AG 159(48.5) 113(43.0) 0.66 0.44-0.97 259(48.7) 131(45.6) 0.75 0.53-1.08 0.71 0.54-0.92
AA 83 (25.3) 59 (22.4) 0.67 0.43-1.06 133(25.0) 62 (21.6) 0.67 0.44-1.03 0.67 0.49-0.91
P trend 0.068 0.059 0.007
STAT1/STAT4
 STAT1 rs2066804 GG 166 (50.3) 164 (62.4) 1.00 296(55.4) 172(60.1) 1.00 1.00
AG 142 (43.0) 85 (32.3) 0.57 0.40-0.81 210(39.3) 103(36.0) 0.85 0.61-1.17 0.71 0.56-0.90
AA 22 (6.7) 14 (5.3) 0.62 0.30-1.27 28 (5.2) 11 (3.9) 0.57 0.27-1.23 0.61 0.36-1.02
P trend 0.004 0.113 0.002
ITGB2
 ITGB2 rs235325 GG 80 (24.2) 91 (34.7) 1.00 177(33.3) 110(38.2) 1.00 1.00
AG 180 (54.6) 127 (48.5) 0.61 0.42-0.89 262(49.3) 137(47.6) 0.84 0.60-1.17 0.73 0.56-0.94
AA 70 (21.2) 44 (16.8) 0.54 0.33-0.88 93 (17.5) 41 (14.2) 0.67 0.42-1.07 0.61 0.43-0.85
P trend 0.007 0.086 0.002
ALOX5
 ALOX5 rs2291427 GG 170 (51.7) 110 (41.8) 1.00 240(44.9) 125(43.4) 1.00 1.00
AG 137 (41.6) 128 (48.7) 1.47 1.04-2.09 244(45.7) 120(41.7) 1.01 0.72-1.40 1.21 0.95-1.53
AA 22 (6.7) 25 (9.5) 1.76 0.93-3.33 50 (9.4) 43 (14.9) 1.85 1.12-3.04 1.85 1.25-2.74
P trend 0.014 0.065 0.003
NFKB1
 NFKB1 rs4647992 CC 315 (95.7) 234 (89.0) 1.00 485(90.7) 257(89.2) 1.00 1.00
CT 14 (4.3) 28 (10.7) 2.85 1.45-5.64 48 (9.0) 31 (10.8) 1.43 0.86-2.39 1.84 1.23-2.73
TT 0 (0.0) 1 (0.4) 2 (0.4) 0 (0.0) 0.00 1.01 0.08-12.36
P trend 0.001 0.340 0.005
IRAK3
 IRAK3 rs2701652 GG 167 (50.8) 152 (57.8) 1.00 243(45.8) 149(51.9) 1.00 1.00
CG 128 (38.9) 85 (32.3) 0.71 0.50-1.02 230(43.3) 122(42.5) 0.86 0.62-1.19 0.80 0.63-1.02
CC 34 (10.3) 26 (9.9) 0.87 0.49-1.53 58 (10.9) 16 (5.6) 0.40 0.22-0.76 0.60 0.40-0.91
P trend 0.191 0.011 0.006
SOD1
 SOD1 rs202445 TT 210 (64.0) 173 (65.8) 1.00 334(63.6) 207(72.4) 1.00 1.00
CT 103 (31.4) 84 (31.9) 0.95 0.66-1.35 169(32.2) 74 (25.9) 0.74 0.52-1.05 0.83 0.65-1.07
CC 15 (4.6) 6 (2.3) 0.46 0.17-1.25 22 (4.2) 5 (1.8) 0.30 0.11-0.84 0.37 0.18-0.74
P trend 0.271 0.007 0.006
NCF2
 NCF2 rs11579965 CC 293(88.8) 221(84.0) 1.00 471(88.2) 239(83.0) 1.00 1.00
CG 35 (10.6) 38 (14.5) 1.48 0.90-2.45 62 (11.6) 48 (16.7) 1.47 0.95-2.27 1.47 1.06-2.04
GG 2 (0.6) 4 (1.5) 2.61 0.46-14.72 1 (0.2) 1 (0.4) 4.24 0.26-69.36 2.99 0.67-13.40
P trend 0.068 0.059 0.007
1

Odds ratio (OR).

2

ORs adjusted for sex, age, study hospital, and distance of residence from hospital.

3

95% confidence intervals.

4

ORs adjusted for sex, age, and state of residence.

5

ORs adjusted for study, sex, residence, and age within each study.

6

D' = 0.99 and r2 = 0.59 for pooled controls of European background.